Modern Biopharmaceuticals Design, Development And Optimization

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched. Over 120 such products are currently being marketed around the world, including nine blockbuster drugs, and nowadays represent the mainstay products of the biotechnology industry. This book is unique in introducing readers to a comprehensive set of recently developed technologies, showing paradigm shifts in the health care system and reflecting these changes in industrial research. Here, the world's top scientists and business leaders divulge their first-hand expertise, allowing you to participate in their recent achievements. They all have their own specific contribution and have been carefully selected to provide a multifaceted and unique insight. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel laureates Robert Huber and Thomas R. Cech, as well as authors from the world's most famous academic institutes and biotech companies, such as ETH Zurich, MIT, Stanford, Yale, Princeton, Harvard Medical School, Max-Planck-Institute, Fraunhofer-Institute, Moscow Academy of Sciences, London Imperial College and Baxter, Invitrogen, MorphoSys, Roche, and Schering AG. The result is a testament to the importance of biotechnology in life science, a sure sign that "Modern Biopharmaceuticals" will fuel biotechnologies and help shape the industry of the future. For pharmaceutists, pharmaceutical chemists, biochemists, molecular biologists, medicinal chemists, as well as those working in the biotechnological and pharmaceutical industries, or biotechnological institutes.Knäblein, Jörg is the author of 'Modern Biopharmaceuticals Design, Development And Optimization', published 2005 under ISBN 9783527311842 and ISBN 352731184X.